Search hospitals > Virginia > Virginia Beach
Peninsula Cancer Institute-Cancer Specialists of Tidewater
Claim this profileVirginia Beach, Virginia 23454
Conducts research for Breast Cancer
Conducts research for Cancer
Conducts research for Colorectal Cancer
Conducts research for Colon Cancer
Conducts research for Adenocarcinoma
18 reported clinical trials
6 medical researchers
Summary
Peninsula Cancer Institute-Cancer Specialists of Tidewater is a medical facility located in Virginia Beach, Virginia. This center is recognized for care of Breast Cancer, Cancer, Colorectal Cancer, Colon Cancer, Adenocarcinoma and other specialties. Peninsula Cancer Institute-Cancer Specialists of Tidewater is involved with conducting 18 clinical trials across 33 conditions. There are 6 research doctors associated with this hospital, such as Khalid Matin, Erin R. Alesi, Asit K. Paul, and Jennifer L. Myers.Area of expertise
1Breast Cancer
HER2 positive
ER positive
ER negative
2Cancer
HER2 positive
Stage IV
ER positive
Top PIs
Khalid MatinVirginia Commonwealth University/Massey Cancer Center5 years of reported clinical research
Studies Colorectal Cancer
Studies Colon Cancer
13 reported clinical trials
29 drugs studied
Erin R. AlesiVirginia Commonwealth University/Massey Cancer Center4 years of reported clinical research
Studies Cancer
Studies Squamous Cell Carcinoma
13 reported clinical trials
19 drugs studied
Asit K. PaulVirginia Commonwealth University/Massey Cancer Center4 years of reported clinical research
Studies Cancer
Studies Bladder Cancer
9 reported clinical trials
26 drugs studied
Jennifer L. MyersVirginia Commonwealth University/Massey Cancer Center4 years of reported clinical research
Studies Bile Duct Cancer
Studies Cancer
8 reported clinical trials
20 drugs studied
Clinical Trials running at Peninsula Cancer Institute-Cancer Specialists of Tidewater
Breast Cancer
Cancer
Colon Cancer
Colorectal Cancer
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Peninsula Cancer Institute-Cancer Specialists of Tidewater?
Peninsula Cancer Institute-Cancer Specialists of Tidewater is a medical facility located in Virginia Beach, Virginia. This center is recognized for care of Breast Cancer, Cancer, Colorectal Cancer, Colon Cancer, Adenocarcinoma and other specialties. Peninsula Cancer Institute-Cancer Specialists of Tidewater is involved with conducting 18 clinical trials across 33 conditions. There are 6 research doctors associated with this hospital, such as Khalid Matin, Erin R. Alesi, Asit K. Paul, and Jennifer L. Myers.